Eterna Therapeutics Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies using messenger ribonucleic acid (RNA) (mRNA) cell engineering technology. The Company has a portfolio of over 100 patents covering mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system, which the Company collectively refers to as its mRNA technology platform. Its mRNA gene-editing technology is designed to delete, insert, and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to fight cancer.
No insider trading activity.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.